End of Year Message from Lupus Research Alliance President & CEO Albert T. Roy
2025 has been an extraordinary year of momentum at the Lupus Research Alliance and clinical affiliate Lupus Therapeutics. Hear...
Albert T. Roy
Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025
4 original posters to be presented on cell therapy, patient-reported outcomes, innovative recruitment strategies, and clinical trial retention...
Welcome to “The Lupus Beacon” — from President & CEO Albert T. Roy
Albert T. Roy, President and CEO of the Lupus Research Alliance, outlines the latest launch of the organization’s new...
Letter from LRA President & CEO Albert T. Roy
Dear Friends,
Lupus Awareness Month officially starts today, and with a growing coalition of people like you passionately working together...
Gazyva® Shows Positive Results in Phase 3 Lupus Nephritis Trial
The Lupus Research Alliance (LRA) and clinical research affiliate Lupus Therapeutics (LT) are excited to share positive news of...
ManyOne ARE Making the Difference
May 1, 2023
Last year, the Lupus Research Alliance launched our ManyOne Can campaign during Lupus Awareness Month to offer...
Lupus Research Alliance Breaking Through Gala Raises Millions for Transformative Lupus Research
NEW YORK, NY. November 22, 2022 – Last night’s Lupus Research Alliance (LRA) Breaking Through Gala at Manhattan’s historic...
Lupus Therapeutics Shifting the Paradigm
The Lupus Research Alliance (LRA)—going bold and thinking big—has once again shifted the status quo of lupus research by...
Battling Lupus with Krill: Phospholipid-rich krill oil a potential new relief option for lupus
August 28, 2018
NEW YORK, NY. Aker BioMarine and Lupus Research Alliance launch a new clinical study, investigating how phospholipid-rich...
Albert T. Roy, Executive Director Lupus Therapeutics, LLC
I’m writing this blog because the Lupus Research Alliance, and its affiliate, Lupus Therapeutics is determined to drive discovery...